
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has reported new clinical evidence suggesting its atrioventricular interval modulation (AVIM) therapy may significantly improve heart function in patients with …
Orchestra BioMed Study Shows AVIM Therapy Could Transform Care for Hypertensive Heart Disease Read More